IP Library Granted Patent US 7,267,959
Granted Patent B2
US 7,267,959 · App. 10/466,313 · Granted Sep 11, 2007

Drug target within the sulfonylurea receptor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,267,959
App. No.
10/466,313
Granted
Sep 11, 2007
Kind
B2
Abstract

It has been found that syntaxin binds and regulates the nucleotide binding folds (NBFs) of sulfonylurea receptors (SURs) in a ATP- and ADP-dependent manner. The present invention therefore provides methods for identifying compounds that effect the binding between a syntaxin protein and a NBF1 and/or NBF2 of a sulfonylurea receptor (SUR). Compounds identified using the method of the invention are useful for treating and/or preventing diseases and/or conditions that have, as their underlying basis, a dysregulation of K AT 191 channels.

Claims (11)

1. A method of screening for compounds that affect the binding between 1) a full Iength syntaxin-1A protein or a fragment thereof which comprises the H3 domain of a syntaxin-1A protein and 2) a nucleotide binding fold-1 (NBF1) and/or nucleotide binding fold-2 (NBF2) protein wherein the NBF1 and/or NBF2 are derived from a sulfonylurea receptor (SUR) selected from the group consisting of SUR1, SUR2A, SUR2B and SUR2C comprising:

(a) contacting the syntaxin-1A protein or the fragment thereof and the NBF1 and/or NBF2 in the presence of a test compound;

(b) determining the effect of the test compound on the binding of the syntaxin-1 A protein or the fragment thereof and the NBF1 and/or NBF2, wherein the syntaxin-1A protein or fragment thereof is capable of binding to NBF1 and/or NBF2, and wherein a difference in the binding between the syntaxin-1A protein or fragment and the NBF1 and/or NBF2 in the presence of the test compound and the binding between the syntaxin-1A protein or fragment and the NBF1 and/or NBF2 in the absence of the test compound (control) indicates that the compound affects the binding between the syntaxin-1A protein or fragment and the NBF1 and/or NBF2.

2. The method according to claim 1 , wherein the SUR is selected from the group consisting of SUR1 and SUR2A.

3. The method according to claim 1 , wherein one of the syntaxin-1A protein or fragment thereof and the NBF1 and/or NBF2 is attached to a solid support.

4. The method according to claim 3 , wherein the solid support is glutathione beads.

5. The method according to claim 3 , wherein binding is measured using antibodies to one of the syntaxin-1A protein and the NBF1 and/or NBF2.

6. The method according to claim 1 wherein the syntaxin-1A comprises the sequence shown in SEQ ID NO:1.

7. The method according to claim 1 wherein the H3 domain comprises amino acid residues 191-266 shown in SEQ ID NO:1.

8. The method according to claim 1 wherein the NBF1 comprises the sequence shown in SEQ ID NO:2 or 4.

9. The method according to claim 8 wherein the NBF2 comprises the sequence shown in SEQ ID NO:3 or 5.

Assignments (1)
CONFIRMATORY LICENSE Recorded Mar 14, 2023
From: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 062976/0220 →
Continuity (2)
Provisional Application 6026469000 · Jan 30, 2001
Related Publication 20040102359A1 · May 27, 2004